1 / 1

Selpercatinib(Retevmo)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

CAPSULE

Validity period:

Not specified in the specification.

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

RETEVMO® (selpercatinib) is an oral, highly selective kinase inhibitor specifically targeting rearranged during transfection (RET) gene alterations. It is available in both capsule and tablet formulations, with dosing regimens tailored according to patient age, body weight, or body surface area, and the presence of hepatic impairment. RETEVMO® is designed to inhibit aberrant RET signaling, which is implicated in the pathogenesis of certain cancers, including NSCLC, medullary thyroid cancer, and other RET fusion-positive solid tumors.

The clinical application of RETEVMO® is based on robust molecular diagnostics to identify eligible patients with RET gene fusions or mutations. Its efficacy and safety have been demonstrated in multiple clinical trials, leading to its approval for use in both adult and pediatric populations. RETEVMO® offers a targeted therapeutic option for patients with limited alternatives, particularly those with disease progression after standard therapies or with tumors refractory to conventional treatments.

Generic name

Selpercatinib(Retevmo)

English name

Selpercatinib

Alternative Names

Retevmo

Drug prices

Indications

RETEVMO is indicated for:

Adult patients with locally advanced/metastatic RET fusion-positive non-small cell lung cancer (NSCLC).

Adults and pediatric patients ≥2 years with:

Advanced/metastatic RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy.

Advanced/metastatic RET fusion-positive thyroid cancer, radioactive iodine-refractory (if appropriate).

Adults and pediatric patients ≥2 years with locally advanced/metastatic RET fusion-positive solid tumors progressing on prior therapy or with no satisfactory alternatives.

Therapeutic Target

RET (wild-type and mutated isoforms). VEGFR1, VEGFR3, FGFR1-3 (at higher concentrations).

Active Ingredients

Selpercatinib

Dosage form

CAPSULE

specifications

Capsules:40 mg: 80 mg

Description

Capsules: Gelatin shell with colloidal silicon dioxide and microcrystalline cellulose.

Tablets: Film-coated with croscarmellose sodium, mannitol, and sodium stearyl fumarate.

Dosage and Administration

Patient Selection: Confirm RET alteration via FDA-approved test.

Dosing:

Adults/Adolescents ≥12 years:

<50 kg: 120 mg twice daily.

≥50 kg: 160 mg twice daily.

Pediatrics 2 to <12 years:

BSA 0.33–0.65 m²: 40 mg thrice daily.

BSA 0.66–1.08 m²: 80 mg twice daily.

BSA 1.09–1.52 m²: 120 mg twice daily.

BSA ≥1.53 m²: 160 mg twice daily.

Administration:

Swallow whole; do not crush/chew.

Withhold for ≥7 days pre-surgery and ≥2 weeks post-major surgery.

Dose Modifications:

Hepatic impairment (severe): Reduce dose (see Table 5).

Adverse reactions: Withhold/reduce dose per severity (Tables 2–3).

Drug interactions: Avoid CYP3A inhibitors/inducers; adjust dose with strong/moderate CYP3A inhibitors (Table 4).

CATEGORY NAVIGATION